ALX Oncology (NASDAQ:ALXO) Earns Buy Rating from HC Wainwright

ALX Oncology (NASDAQ:ALXOGet Free Report)‘s stock had its “buy” rating reissued by analysts at HC Wainwright in a research note issued on Monday, Benzinga reports. They currently have a $25.00 price objective on the stock. HC Wainwright’s target price points to a potential upside of 177.47% from the stock’s previous close.

A number of other equities research analysts also recently weighed in on the company. Stifel Nicolaus restated a “hold” rating and issued a $14.00 target price (up from $10.00) on shares of ALX Oncology in a research report on Friday, March 8th. Cantor Fitzgerald restated an “overweight” rating on shares of ALX Oncology in a research report on Wednesday, May 29th. One analyst has rated the stock with a hold rating and five have assigned a buy rating to the stock. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $19.67.

View Our Latest Report on ALXO

ALX Oncology Stock Down 2.9 %

NASDAQ:ALXO opened at $9.01 on Monday. The company has a current ratio of 5.21, a quick ratio of 5.21 and a debt-to-equity ratio of 0.06. The stock has a 50 day moving average of $13.74 and a 200-day moving average of $13.50. The firm has a market capitalization of $469.42 million, a PE ratio of -2.42 and a beta of 1.16. ALX Oncology has a 52 week low of $3.94 and a 52 week high of $17.83.

ALX Oncology (NASDAQ:ALXOGet Free Report) last issued its quarterly earnings data on Thursday, May 9th. The company reported ($0.71) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.87) by $0.16. Analysts predict that ALX Oncology will post -2.89 EPS for the current year.

Insider Buying and Selling at ALX Oncology

In other news, CEO Jason Lettmann bought 4,400 shares of the business’s stock in a transaction on Thursday, March 14th. The shares were bought at an average cost of $11.31 per share, with a total value of $49,764.00. Following the purchase, the chief executive officer now directly owns 171,620 shares in the company, valued at $1,941,022.20. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. In other news, insider Jaume Pons sold 20,000 shares of the company’s stock in a transaction on Thursday, April 4th. The shares were sold at an average price of $11.15, for a total value of $223,000.00. Following the transaction, the insider now directly owns 628,359 shares of the company’s stock, valued at $7,006,202.85. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, CEO Jason Lettmann purchased 4,400 shares of the company’s stock in a transaction dated Thursday, March 14th. The stock was bought at an average cost of $11.31 per share, for a total transaction of $49,764.00. Following the completion of the purchase, the chief executive officer now directly owns 171,620 shares of the company’s stock, valued at approximately $1,941,022.20. The disclosure for this purchase can be found here. Insiders have sold a total of 122,000 shares of company stock valued at $1,611,280 in the last three months. 33.40% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On ALX Oncology

A number of hedge funds have recently modified their holdings of ALXO. Barclays PLC increased its stake in shares of ALX Oncology by 57.1% in the third quarter. Barclays PLC now owns 26,964 shares of the company’s stock worth $129,000 after acquiring an additional 9,796 shares during the last quarter. J.P. Morgan Private Wealth Advisors LLC bought a new stake in ALX Oncology in the third quarter worth $96,000. Hsbc Holdings PLC bought a new stake in ALX Oncology in the third quarter worth $168,000. SG Americas Securities LLC boosted its holdings in ALX Oncology by 201.4% in the fourth quarter. SG Americas Securities LLC now owns 30,348 shares of the company’s stock worth $452,000 after purchasing an additional 20,279 shares in the last quarter. Finally, China Universal Asset Management Co. Ltd. boosted its holdings in ALX Oncology by 445.6% in the fourth quarter. China Universal Asset Management Co. Ltd. now owns 5,762 shares of the company’s stock worth $86,000 after purchasing an additional 4,706 shares in the last quarter. 97.97% of the stock is owned by institutional investors and hedge funds.

ALX Oncology Company Profile

(Get Free Report)

ALX Oncology Holdings Inc, a clinical-stage immuno-oncology company, focuses on developing therapies for cancer patients in the United States. The company's lead product candidate is Evorpacept, a CD47 blocking therapeutic biologic in development as a combination therapy with other anti-cancer agents, including ASPEN-06, under Phase 2 clinical study for treating Gastric/GEJ cancer; ASPEN-07, under Phase 1 clinical study for treating urothelial cancer; and ASPEN-03 and ASPEN-04, both under Phase 2 clinical study for treating head and neck squamous cell carcinoma.

Recommended Stories

Analyst Recommendations for ALX Oncology (NASDAQ:ALXO)

Receive News & Ratings for ALX Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ALX Oncology and related companies with MarketBeat.com's FREE daily email newsletter.